Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
Tóm tắt
Từ khóa
Tài liệu tham khảo
J Ferlay, ISoerjomataram, MErviket al. GLOBOCAN 2012 v 1.0, Cancer Incidence and Mortality Worldwide. 2013. Lyon, International Agency for Research on Cancer. IARC CancerBase No. 11.
Coates, 2015, Evolution of the St. Gallen Consensus process for the optimal treatment of women with breast cancer, Breast, 24, PG 0.1
Pagani, 2014, Adjuvant exemestane with ovarian suppression in premenopausal breast cancer, N Engl J Med, 371, 107, 10.1056/NEJMoa1404037
Francis, 2015, Adjuvant ovarian suppression in premenopausal breast cancer, N Engl J Med, 372, 436, 10.1056/NEJMoa1412379
Moore, 2015, Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy, N Engl J Med, 372, 923, 10.1056/NEJMoa1413204
Dengel, 2014, Axillary dissection can be avoided in the majority of clinically node-negative patients undergoing breast-conserving therapy, Ann Surg Oncol, 21, 22, 10.1245/s10434-013-3200-6
Moran, 2014, Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer, J Clin Oncol, 32, 1507, 10.1200/JCO.2013.53.3935
Whelan, 2011, NCIC-CTG MA.20: an intergroup trial of regional nodal irradiation in early breast cancer, J Clin Oncol Proceedings of the American Society of Clinical Oncology, 29
Poortmans, 2013, Lymph node radiotherapy improves survival in breast cancer: 10 year results of the EORTC Radiation Oncology and Breast Cancer Groups phase III trial 22922/10925, ESTRO Congress Report, 6
Nordenskjold, 2015, No clear effect of postoperative radiotherapy on survival of breast cancer patients with 1–3 positive nodes: a population-based study, Ann Oncol, 26, 1149, 10.1093/annonc/mdv159
Whelan, 2010, Long-term results of hypofractionated radiation therapy for breast cancer, N Engl J Med, 362, 513, 10.1056/NEJMoa0906260
Haviland, 2013, The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials, Lancet Oncol, 14, 1086, 10.1016/S1470-2045(13)70386-3
The Cancer Genome Atlas Network, 2012, Comprehensive molecular portraits of human breast tumours, Nature, 490, 61, 10.1038/nature11412
Sorlie, 2001, Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications, Proc Natl Acad Sci USA, 98, 10869, 10.1073/pnas.191367098
Bastien, 2012, PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers, BMC Med Genomics, 5, 44, 10.1186/1755-8794-5-44
Bayraktar, 2014, Molecular subtyping predicts pathologic tumor response in early-stage breast cancer treated with neoadjuvant docetaxel plus capecitabine with or without trastuzumab chemotherapy, Med Oncol, 31, 163, 10.1007/s12032-014-0163-9
Dowsett, 2013, Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy, J Clin Oncol, 31, 2783, 10.1200/JCO.2012.46.1558
Eiermann, 2013, The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use, Ann Oncol, 24, 618, 10.1093/annonc/mds512
Prat, 2013, Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer, J Clin Oncol, 31, 203, 10.1200/JCO.2012.43.4134
Nielsen, 2010, A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer, Clin Cancer Res, 16, 5222, 10.1158/1078-0432.CCR-10-1282
Coates, 2012, Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IX, Breast Cancer Res, 14, R143, 10.1186/bcr3348
Regan, 2008, Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?, Ann Oncol, 19, 1231, 10.1093/annonc/mdn037
Wirapati, 2008, Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures, Breast Cancer Res, 10, R65, 10.1186/bcr2124
de Azambuja, 2007, Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients, Br J Cancer, 96, 1504, 10.1038/sj.bjc.6603756
Criscitiello, 2014, High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in luminal B HER2 negative and node-positive breast cancer, Breast, 23, 69, 10.1016/j.breast.2013.11.007
Denkert, 2014, Reply to Ki67 in breast cancer: a useful prognostic marker!, Ann Oncol, 25, 542, 10.1093/annonc/mdt564
Polley, 2013, An international Ki67 reproducibility study, J Natl Cancer Inst, 105, 1897, 10.1093/jnci/djt306
Bouganim, 2013, Evolution of sites of recurrence after early breast cancer over the last 20 years: implications for patient care and future research, Breast Cancer Res Treat, 139, 603, 10.1007/s10549-013-2561-7
Houssami, 2014, Margins in breast conservation: a clinician's perspective and what the literature tells us, J Surg Oncol, 110, 2, 10.1002/jso.23594
Giuliano, 2011, Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis, JAMA, 305, 569, 10.1001/jama.2011.90
Donker, 2014, Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial, Lancet Oncol, 15, 1303, 10.1016/S1470-2045(14)70460-7
Wolmark, 2014, Recurrence score and quantitative ER expression to predict in late distant recurrence risk in ER+ BC after 5 years of tamoxifen, J Clin Oncol, 32
Nielsen, 2014, Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens, BMC Cancer, 14, 177, 10.1186/1471-2407-14-177
Sestak, 2013, Factors predicting late recurrence for estrogen receptor-positive breast cancer, J Natl Cancer Inst Monogr, 105, 1504, 10.1093/jnci/djt244
Dubsky, 2013, The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients, Br J Cancer, 109, 2959, 10.1038/bjc.2013.671
Zhang, 2013, Breast cancer index identifies early-stage estrogen receptor-positive breast cancer patients at risk for early- and late-distant recurrence, Clin Cancer Res, 19, 4196, 10.1158/1078-0432.CCR-13-0804
Del Mastro, 2011, Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer, JAMA, 306, 269
Gerber, 2011, Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study, J Clin Oncol, 29, 2334, 10.1200/JCO.2010.32.5704
Sledge, 2013, ASCO's approach to a learning health care system in oncology, J Oncol Pract, 9, 145, 10.1200/JOP.2013.000957
Campbell, 2015, Interpreting genomics data at a functional level: what are we learning from large molecular screening projects?, Breast, 24, PG 2.01
Viale, 2014, High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trial, Ann Oncol, 25, 816, 10.1093/annonc/mdu026
Reis-Filho, 2015, Discrepancies between genetic tools and immunohistochemistry: bad pathology and good signature, and vice-versa, Breast, 24, PG 2.03
Maisonneuve, 2014, Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes, Breast Cancer Res, 16, R65, 10.1186/bcr3679
Viale, 2015, A bad tumor biomarker is as bad as a bad drug: the gap between genomics data and phenotype to predict response, Breast, 24, PG 2.04
Prat, 2014, Research-based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study, Clin Cancer Res, 20, 511, 10.1158/1078-0432.CCR-13-0239
Schneeweiss, 2013, Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA), Ann Oncol, 24, 2278, 10.1093/annonc/mdt182
Schneeweiss, 2014, Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA study, Breast Cancer Res, 16, R73, 10.1186/bcr3690
Prat, 2013, Molecular characterization of basal-like and non-basal-like triple-negative breast cancer, Oncologist, 18, 123, 10.1634/theoncologist.2012-0397
Loibl, 2015, Primary systemic therapy for clinicians: medical and research perspectives, Breast, 24, PG 8.01
Masuda, 2013, Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes, Clin Cancer Res, 19, 5533, 10.1158/1078-0432.CCR-13-0799
Lehmann, 2011, Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies, J Clin Invest, 121, 2750, 10.1172/JCI45014
Adams, 2014, Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199, J Clin Oncol, 32, 2959, 10.1200/JCO.2013.55.0491
Loi, 2014, Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial, Ann Oncol, 25, 1544, 10.1093/annonc/mdu112
Perez, 2015, Stromal tumor-infiltrating lymphocytes (S-TILs): in the alliance N9831 trial S-TILs are associated with chemotherapy benefit but not associated with trastuzumab benefit, Cancer Res, 75, 10.1158/1538-7445.SABCS14-S1-06
Milagre, 2015, Adaptive upregulation of EGFR limits attenuation of tumor growth by neutralizing IL6 antibodies, with implications for combined therapy in ovarian cancer, Cancer Res, 10.1158/0008-5472.CAN-14-1801
Herbst, 2014, Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients, Nature, 515, 563, 10.1038/nature14011
Curigliano, 2015, Immune pathways and immunome as a target, Breast, 24, PG 4.02
Nanda, 2015, A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer, Cancer Res Suppl, S1-09, 10.1158/1538-7445.SABCS14-S1-09
Finn, 2015, The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study, Lancet Oncol, 16, 25, 10.1016/S1470-2045(14)71159-3
Telli, 2015, Phase II study of gemcitabine, carboplatin, and iniparib as neoadjuvant therapy for triple-negative and BRCA1/2 mutation-associated breast cancer with assessment of a tumor-based measure of genomic instability: PrECOG 0105, J Clin Oncol, 10.1200/JCO.2014.57.0085
von Minckwitz, 2014, Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple-negative breast cancer (TNBC): results from GeparSixto, J Clin Oncol, 32
Tutt, 2014, TNT: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer CRUK/07/012), Cancer Res Suppl, 75, S3-01, 10.1158/1538-7445.SABCS14-S3-01
Baselga, 2015, Targeting PIK3CA pathway, Breast, 24, PG 5.03
Andre, 2013, Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer, Clin Cancer Res, 19, 3693, 10.1158/1078-0432.CCR-13-0190
Soria, 2014, Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors, Ann Oncol, 25, 2244, 10.1093/annonc/mdu390
Phillips, 2013, Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers, J Clin Oncol, 31, 3091, 10.1200/JCO.2012.47.8313
Hartmann, 2015, Atypical hyperplasia of the breast—risk assessment and management options, N Engl J Med, 372, 78, 10.1056/NEJMsr1407164
Yi, 2014, Which threshold for ER positivity? A retrospective study based on 9639 patients, Ann Oncol, 25, 1004, 10.1093/annonc/mdu053
Feng, 2014, An epigenomic approach to therapy for tamoxifen-resistant breast cancer, Cell Res, 24, 809, 10.1038/cr.2014.71
Denkert, 2013, Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial, Ann Oncol, 24, 2786, 10.1093/annonc/mdt350
Denkert, 2015, Developing Ki67 as a useful marker, Breast, 24, PG 7.04
Polley, 2015, An international study to increase concordance in Ki67 scoring, Mod Pathol, 28, 778, 10.1038/modpathol.2015.38
Klauschen, 2014, Standardized Ki67 diagnostics using automated scoring—clinical validation in the GeparTrio Breast Cancer study, Clin Cancer Res
von Minckwitz, 2014, Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial, Lancet Oncol, 15, 747, 10.1016/S1470-2045(14)70160-3
Denkert, 2015, Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers, J Clin Oncol, 33, 983, 10.1200/JCO.2014.58.1967
Loibl, 2014, PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (HER2) therapy in primary HER2-overexpressing breast cancer, J Clin Oncol, 10.1200/JCO.2014.55.7876
Majewski, 2015, PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer, J Clin Oncol, 10.1200/JCO.2014.55.2158
V Guarneri, MDieci, LCarbogninet al. Activity of neoadjuvant lapatinib plus trastuzumab for early breast cancer according to PIK3CA mutations: pathological complete response (pCR) rate in the CherLOB study and pooled analysis of randomized trials. Ann Oncol 2014; 25(Suppl 4): iv85–iv109.
Allevi, 2013, Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer, Br J Cancer, 108, 1587, 10.1038/bjc.2013.151
Dowsett, 2007, Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer, J Natl Cancer Inst, 99, 167, 10.1093/jnci/djk020
Dowsett, 2015, Neoadjuvant endocrine therapy: patient selection, treatment duration and surrogate endpoints, Breast, 24, PG 8.02
de Azambuja, 2014, Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response, Lancet Oncol, 15, 1137, 10.1016/S1470-2045(14)70320-1
Piccart-Gebhart, 2015, J Clin Oncol, 32, LBA 4
DeMichele, 2015, The neoadjuvant model is still the future for drug development in breast cancer, Clin Cancer Res, 21, 2911, 10.1158/1078-0432.CCR-14-1760
Yao, 2013, Contralateral prophylactic mastectomy and survival: report from the National Cancer Data Base, 1998–2002, Breast Cancer Res Treat, 142, 465, 10.1007/s10549-013-2745-1
Narod, 2011, The impact of contralateral mastectomy on mortality in BRCA1 and BRCA2 mutation carriers with breast cancer, Breast Cancer Res Treat, 128, 581, 10.1007/s10549-011-1479-1
Kurian, 2014, Use of and mortality after bilateral mastectomy compared with other surgical treatments for breast cancer in California, 1998–2011, JAMA, 312, 902, 10.1001/jama.2014.10707
Guth, 2012, Increasing rates of contralateral prophylactic mastectomy—a trend made in USA?, Eur J Surg Oncol, 38, 296, 10.1016/j.ejso.2011.12.014
Partridge, 2013, Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: results from a herceptin adjuvant trial, J Clin Oncol, 31, 2692, 10.1200/JCO.2012.44.1956
Kuehn, 2013, Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study, Lancet Oncol, 14, 609, 10.1016/S1470-2045(13)70166-9
Boileau, 2015, Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC Study, J Clin Oncol, 33, 258, 10.1200/JCO.2014.55.7827
Boughey, 2015, Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 (Alliance), Ann Surg, 261, 547, 10.1097/SLA.0000000000000551
Galimberti, 2015, Feasibility of sentinel node biopsy in breast cancer after neoadjuvant treatment, Breast, 24, PG 9.02
Ataseven, 2015, Impact of multifocal or multicentric disease on surgery and locoregional, distant and overall survival of 6,134 breast cancer patients treated with neoadjuvant chemotherapy, Ann Surg Oncol, 22, 1118, 10.1245/s10434-014-4122-7
Yarnold, 2015, Hypofractionated radiotherapy in early breast cancer: clinical, dosimetric and radio-genomic issues, Breast, 24, PG 10.01
Whelan, 2015, Evolving standards in breast cancer radiotherapy: who should receive locoregional RT?, Breast, 24, PG 10.02
Thorsen, 2014, CT-planned internal mammary node radiotherapy in the DBCG-IMN study: benefit versus potentially harmful effects, Acta Oncol, 53, 1027, 10.3109/0284186X.2014.925579
Gnant, 2015, Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12, Ann Oncol, 26, 313, 10.1093/annonc/mdu544
Tevaarwerk, 2014, Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group, J Clin Oncol, 32, 3948, 10.1200/JCO.2014.55.6993
Ribi, 2014, Cancer Res Suppl, S3-09
Bernhard, 2015, J Clin Oncol, 32, #557
Regan, 2015, Predicting benefit of endocrine therapy, Breast, 24, PG 11.03
Viale, 2011, Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1–98 randomized trial, Ann Oncol, 22, 2201, 10.1093/annonc/mdq738
Goodwin, 2015, Obesity and insulin resistance: clinical relevance and research priorities, Breast, 24, PG 6.03
Shulman, 2012, Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101, J Clin Oncol, 30, 4071, 10.1200/JCO.2011.40.6405
Wolff, 2015, Risk of marrow neoplasms after adjuvant breast cancer therapy: The National Comprehensive Cancer Network Experience, J Clin Oncol, 33, 340, 10.1200/JCO.2013.54.6119
Eckhoff, 2015, Persistence of docetaxel-induced neuropathy and impact on quality of life among breast cancer survivors, Eur J Cancer, 51, 292, 10.1016/j.ejca.2014.11.024
de Azambuja, 2014, Trastuzumab-associated cardiac events at 8 years of median follow-up in the herceptin adjuvant trial (BIG 1-01), J Clin Oncol, 32, 2159, 10.1200/JCO.2013.53.9288
Tolaney, 2015, Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer, N Engl J Med, 372, 134, 10.1056/NEJMoa1406281
Pagani, 2015, Pregnancy after breast cancer: are young patients willing to participate in clinical studies?, Breast, 24, 201, 10.1016/j.breast.2015.01.005
Early Breast Cancer Trialists' Collaborative Group, 2012, Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome in 100,000 randomised women in 123 randomised trials, Lancet, 379, 432, 10.1016/S0140-6736(11)61625-5
Hart, 2015, Defining optimal duration and predicting benefit from chemotherapy in patients with luminal-like subtypes, Breast, 24, PG 12.02
Slamon, 2011, Adjuvant trastuzumab in HER2-positive breast cancer, N Engl J Med, 365, 1273, 10.1056/NEJMoa0910383